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Structural Factors in the In Vivo Chelate
Mobilization of Aged Cadmium Deposits
by Pramod K. Singh,* Shirley G. Jones,* and Mark M. Jones*
Theroleofstructural factorsindeterminingtherelativeefficacyofdithiocarbamates aschelating
agents for the in vivo mobilization ofaged cadmium deposits is examined for 23 newly synthesized
compounds ofthistype. Thecriticalfeatureindeterminingtheefficacyofthecompounds inmobiliz-
ingintracellular cadmium is thebalancebetweenhydrophobic andhydrophilic groups. Thisbalance
also governs the otherproperties ofthese compounds such as the organ specificity ofactionandthe
relativepropensitytocarrycadmiumtothebrain. Thetransportofcadmiumtothebrainbydithiocar-
bamate canbe greatly reduced by the incorporation ofappropriate hydrophilic groups that prevent
the formation oflipid-soluble cadmium complexes that pass readily into the brain. Ifthe chelating
agents carry an additional ionic charge, their ability to pass through cellular membranes and react
with intracellular deposits ofcadmium is significantly reduced, with other structural factors being
equal. The structural features thatoptimize mobilization ofcadmiumfromthekidney do not appear
to be identical with those that optimize its mobilization from the liver. The correlation ofcadmium-
mobilizing properties ofthese chelating agents with the sum ofthe Hansch n constants for the parts
ofthe molecular structures other than the dithiocarbamate grouping (lIn) is reasonably good for the
removal of renal cadmium by derivatives of D-glucamine and D-xylamine. Another aspect of the
molecular structure that appears toplayarole isthepresence ofuncharged polargroupshavingthe
abilitytoformhydrogenbonds.Therelevanceofthesefactorsindesigningchelatingagentstoenhance
the excretion of other toxic metals from their intracellular sites is discussed.
Introduction
Humaningestionoftoxicmetalsfromtheenvironment
is amatterofcontinuingconcern. For manysuchmetals,
treatments based onusingchelatingagents areavailable
for useinclinics. Ingeneral, the successofthetreatment
depends uponthetimeintervalbetween exposure orin-
gestionofthetoxicmetalandtheinitiationoftreatment.
Earlytreatmentallowsthatmetalwhichisingestedbut
not absorbed, for example, from the gastrointestinal
tract, to be more effectively removed. As this time in-
tervalincreases, theamountofmetalabsorbedincreases,
and agreaterproportionoftheabsorbedmetal canreach
intracellularsiteswhereitsremovalisoftendifficult. For
many toxic metals there are very few chelating agents
that have been used successfully in the treatment of
heavymetaltoxicitywhensuchtreatmentisdelayedfor
an extended period of time. As a result, the structural
requirements needed to insure efficacy in such com-
pounds arenotclearlyunderstood. Wehave, accordingly,
undertakenthestudyofanextensiveseriesofdithiocar-
bamates in the mobilization of cadmium from its aged
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deposits in mice in order to sort out the structural fac-
torsthatarefavorabletotheefficacyofsuchcompounds
when treatment is delayed. The results obtained may
serve as a guide in designing more effective chelating
agents forthe delayed treatment oftoxicity because of
other environmentally important toxic metals.
Theabilityofsodiumdiethyldithiocarbamate(DDTXC)
to act as an antagonist for acute cadmium chloride in-
toxicationwasfirstreportedbyGaleandhisco-workers
(1). Subsequent studies have confirmed and extended
these results and showed that dithiocarbamates are
capable of reacting with and mobilizing intracellular
deposits of cadmium (2-10), a significant environmen-
talpoison. The ability ofthe cadmium complex, that is
formedwithDUDTC, topassthroughtheblood-brainbar-
rierresultsinanincreaseinthebrainlevelsofcadmium
in such a situation (4). It was shown that the use of
dithiocarbamatesbearingmorepolarsubstituents onthe
nitrogenpreventedthispassageofthedithiocarbamate-
cadmiumcomplexthroughtheblood-brainbarrier(5,8).
Subsequenttothesefindings alarge numberofdithi-
ocarbamates have been developed, which are capable
ofremovingagedcadmiumfromitsintracellulardeposits
inthe liver, thekidney, and someotherorgans, without
simultaneously transferring anyofthe cadmium to the
brain. Formost ofthe compounds providing data, theySINGH, JONES, AND JONES
are found to enhance the biliary excretion of cadmium
(11) and cause an appreciable increase in the fecal ex-
cretion of cadmium (3,7,12-15). These results are of
general interest because the majority of therapeutic
chelatingagentsusedtoremovetoxicheavymetalsfrom
the mammalian body are unable to gain access to such
intracellular deposits.
Whilethetypicalapproachtodevelopingmoreeffica-
cioustherapeutic chelatingagentsfortoxicmetalsisvia
asystematicstudyofthefactorsthataffectthestability
constants of the metal complexes that are formed
(16-19), thisapproachhasnotbeentakeninthepresent
study because of the solubility problems that arise in
determiningthe stability constants ofdithiocarbamate-
cadmiumcomplexes(20). Instead, wehavetakenanap-
proach where the effect of structural variations on
biological properties, associated with a specific func-
tional group in a molecule, have been used to indicate
thedirectioninwhichfuture synthetic effortshouldbe
directed. This has been useful because, in the present
case at least, the pharmacological properties of the
chelating agent are of key significance in determining
whetherthatcompound isabletogainaccessto, andto
mobilize intracellular deposits ofcadmium invivo. Fol-
lowing ingestion, cadmium moves rapidly to intra-
cellularsites(21)wheretypicalwater-soluble chelating
agents(eventhosewithveryhighvaluesfortheirstabili-
ty constants with cadmium) are unable to remove it
(22-26). Thus, an approach based solely on structural
variationsdesignedtooptimizethestabilityconstantof
thecomplexofthecadmiumionwiththechelatingagent
wasshown nottobeafruitfulapproach inearlystudies
(22-25). The only type of chelating group, other than
dithiocarbamate thathasbeenshowncapableofmobiliz-
ing intracellular cadmium, is the vicinal dithiol group,
whichhasbeenexaminedinsomedetailbyCherianand
hisco-workers (27,28). Themobilization ofintracellular
cadmium is also a problem in which the rates of the
variousprocessesinvolvedarecriticalindeterminingthe
extentofcadmiummobilizationthatisachieved(29).The
present study started from the demonstrated ability of
the dithiocarbamate moiety to remove cadmium from
its aged deposits in vivo.
It is customary in most structure-activity studies to
determinetheconcentration atwhichagivenbiological
effectisobtained with different compounds. Studiesin
which atoxic metal is removed from animals would re-
quire an enormous number of animals, many experi-
ments, and an extended period of time for each com-
pound for the collection of such data. It is much more
convenient, as well as customary, to use a standard set
ofconditionsinwhichalltheanimalsareloadedthesame
way with the toxic metal and then each of the groups
is subjected to a standard mobilization procedure with
the administration ofexactly the same molar dosage of
chelating agent. The results ofsuch experiments allow
thechelatingagentstoberanked onthebasisofrelative
efficacy(foreachoftheimportantorgansifnecessary),
andthenthisrelativeefficacycanbeexaminedtodeter-
mine the correlation of the trend of mobilizing ability
with various structural changes.
Anotherproblemthatariseswithsuchcorrelationsin-
volving many chelating agents is the presence of ionic
groups. Such groups are essential for proper function-
ingofthechelatingagentsand canrarelybe eliminated
fromthestructures. Sinceitisgenerallyconsideredthat
the assignment of T contributionsforsuchpolargroups
isdifficult, thevaluesforsuchgroupingsareusually not
foundinstandardcompilations. Whileestimatesforthe
values of these substituent constants can be obtained
fromtheliterature(15,30), themannerinwhichthey-are
to be incorporated into standard compilations is some-
what arbitrary. An additional complication that arises
withseveralofthecompoundspreparedhereisthevari-
ation inthe valuesforaromatic-aliphatic combinations
ofthe sort used here(31); thusthe i value ofthebenzyl
groupisquitedependentonthegroupattachedtoit, and
these values have not been estimated for the dithio-
carbamates. The net result is that structure-activity
studies can be carried out on these systems, but not in
quite the same manner as is customary with a series of
electrically neutral organic compounds.
Experimental Section
Preparation of N-Substituted Xylamines
(7a-m), and Glucamines (lOf-h, j-m).
All the substituted xylamines and glucamines were
prepared by following a reported procedure (47) with
some variation (34). In general, for Schiff base forma-
tion, D-(+)xylose (6) ora-D-(+)-glucose (9) is allowed to
reactwithaslightexcess(ca. 1-2%)ofamine(5a-m)until
gelformationoraviscousoilyreactionmixtureisobtain-
edtoensurecompletionofthereaction. Hydrogenation
wascarried outasusual(34)inthepresence ofplatinum
oxide catalyst. In cases where solid product could not
be isolated, the highly viscous oil was used as such in
the next step (libles 1 and 2).
Preparation of Dithiocarbamates
(2, 4a,b, 8a-m, 11f-h, j-m)
The reported(33,34) procedure was successfully em-
ployed to obtain dithiocarbamates as white solids. For
thepreparationof2and4a,b, 2moleofNaOHwasused,
whereasforthe rest(8a-m, and 11f-h,j-m)only 1 mole
was used. The amines were dissolved preferably in 1,4-
dioxane, but occasionally methanol was used due to
solubility reasons. The products were characterized by
IR, 'H NMR(300 MHz) and elemental analyses (l1bles
3-5).
Animal Studies
Male ICR mice (Harlan Industries, Indianapolis, IN)
weighing 31 ± 2gwereloadedwithcadmiumviaaseries
ofIPinjectionsbyadministeringone 1-mgandthree3-mg
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lkble 1. Substituted xylamines 7a-m, RNHCH2(CHOH)3CH20H.
Compound number R Yield, % Melting point, IC
7a C6H5CH2 81.3 44-46
7b 3-CF3C6H4CH2 75.5 82-85
7c 4-CH3C6H4CH2 81.6 91-94
7d 4-CH3OC6H4CH2 71.9 75-77
7e 4-C1C6H4CH2 72.6 54-57
7f C6H,(CH2)3 95.0a (Highly viscous oil)b
7g C6H5(CH2)4 96.0a (Highly viscous oil)b
7h CH3(CH2)5 63.9 70-72
7i CH3(CH2)6 73.9 71-73
7j CH3(CH2)7 83.0 75-77
7k CH3(CH2)A 68.7 82-84
71 c-C6H,,(cyclohexyl) 50.8 108-110
7m O(CH2CH2)2N(CH2)3 95.0a (Viscous oil)b
aYield refers to crude product which was used as such in the next step.
bObtained as viscous oil and could not be crystallized.
Compound number
lOf
log
10h
lOj
10k
101
lom
Table 2. Substituted glucamines 10 f-hj-m, RNHCH2(CHOH)4CH20H.
R Yield, %
C6H5(CH2)3 40.9
C6H5(CH2)4 49.4
CH3(CH2)5 61.0
CH3(CH2)7 70.7
CH3(CH2)A 35.8
c-C6H,,(cyclohexyl) 50.8
O(CH2CH2)2N(CH2)3 73.1
Melting point, IC
147-149
123-124
120-122
121-123
122-124
138-140
113-115
Ibble 3. Dithiocarbamates of amino acids 2, 4a,b.
Compound number R Formula, anal. Yield, % Melting point, OC 'H NMR (D20/DSS), 6, ppm
2*0.5 H20 - C,OHgNNa2O2S2e0.5 H20 65.0 >250 7.32-7.14(m, 5H), 5.28(s, 2H), 4.43(s, 2H)
(C,H,N,Sa)
4a 0.0 H20 H C6H7NNa2O2S2*O.0 H20 95.0 >300 4.84-4.81 (m, 1H), 3.96-3.75 (m, 2H),
(C,H,N,S) 2.38-2.26 (m, 1H), 2.09-1.95 (m, 3H)
4b* 1.2 H20 OH C6H7NNa2O3S2* 1.2 H20 90.8 191-195 4.83 (t, J=7.7 Hz, 1H), 4.55-4.49 (m, 1H),
(Cb,H,N,sc) 4.17-4.13 (2t, J=13.2, 1.4 Hz, 1H), 3.97-3.93 (2d, J=13.2, 4.9 Hz, 1H),
2.44-2.35 (m, 1H), 2.27-2.18 (m, 1H)
as, calculated 21.79 (found 19.96). Analysis not within ± 0.40%.
bC, calculated 26.41 (found 27.10). Analysis not within + 0.40 %.
CS, calculated 23.50 (found 23.07). Analysis not within + 0.40%.
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Ihble 4. Substituted xylamine dithioc
Compound number R Formula, anal. Yield, % Mell
8a * 0.8 H20 C6H5CH2 C,3H,8NNaO4S2 * 0.8 H20 71.0
(C,H,N,Sa)
8b * 2.3 H20 3-CF3C6H4CH2
8c * 0.7 H20 4-CH3C6H4CH2
C,4H17F3NNaO4S2 * 2.3 H20
(C,H,N,S)
C14H2(,NNaO4S2 * 0.7 H20
(C,H,N,S)
8d * 0.0 H20 4-CH3OC6H4CH2 C,4H2(,NNaO5S2 * 0.0 H20
(C,H,N,S)
8e * 1.0 H20 4-ClC6H4CH2 C13H,7ClNNaO4S2 * 1.0 H20
(C,H,N,S)
8f * 1.2 H20 C6H5(CH2)3 C,5H22NNaO4S2 * 1.2 H20
(C,H,N,Sb)
8g * 1.2 H20 C6H5(CH2)4 C16H24NA04S2 * 1.2 H20
(C,Hc N,Sd)
8h * 1.0 H20 CH3(CH2)5 C12H24NNaO4S2 * 1.0 H20
(C,H,N,S)
8i * 0.8 H20 CH3(CH2)6 C,3H26NNaO4S2 * 0.8 H20
(C,H,N,S)
8j * 0.8 H20 CH3(CH2)7 C,4H28NNaO4S2 * 0.8 H20
(C,H,N,S)
8k * 0.5 H20 CH3(CH2)9 C16H32NNaO4S2 * 0.5 H20
(C,H,N,S)
81 0.4 H20 c-C6H,l C,2H22NNaO4S2 * 0.4 H20
(C,H,N,Se)
8m * 0.0 H20 O(CH2CH2) CC,3H25N2NaO5S2 * 0.0 H20
2N(CH2)3 (C,H,N,S)
43.3
69.9
83.2
50.7
47.3
69.0
75.0
88.6
82.8
89.8
67.7
89.5
as, calculated 18.12 (found 18.72). Analysis not within 0.40%.
bS,
calculated 16.48
(found 17.77).
Analysis not within ±
0.40%.
CH,
calculated 6.60
(found 6.14).
Analysis not within ±
0.40%. CH,
calculated 15.91
(found 14.15).
Analysis not within ±
0.40%.
es,
calculated 18.94
(found 18.11).
Analysis not within ±
0.40%.
arbamates 8a-m.
ting point, OC 'H NMR (D20/DSS), 6, ppm
185-186 7.44-7.21 (m, 5H), 5.75 (d, J=15.8 Hz, 1H),
5.25 (d, J=15.8 Hz, 1H), 4.44-4.39
(dd, J=13.7, 4.9 Hz, 1H), 4.28-4.23
(m, 1H), 3.98-3.94 (dd, J=14.1, 8.3 Hz,
1H) 3.84-3.79 (m, 1H), 3.67-3.63
(dd, J=11.8, 3.9 Hz, 1H), 3.58-3.50
(m, 2H).
160-162 7.66-7.49 (m, 4H), 5.81 (d, J=16.1 Hz,
1H), 5.32 (d, J=16.1 Hz, 1H), 4.48-4.43
(dd, J=13.8, 4.8 Hz, 1H), 4.31-4.26
(m, 1H), 3.99-3.95 (dd, J=13.7, 8.1 Hz,
1H), 3.86-3.80 (m, 1H), 3.71-3.52 (m, 3H).
215-217 7.25 (d, J=8.1 Hz, 2H), 7.19 (d, J=8.1 Hz,
2H), 5.71 (d, 15.6 Hz, 1H), 5.19 (d,
J = 15.6 Hz, 1H), 4.41-4.36 (dd, J=13.8,
4.9 Hz, 1H), 4.25-4.20 (m, 1H), 3.96-3.92
(dd, J=13.7, 7.9 Hz, 1H), 3.84-3.78 (m,
1H), 3.66-3.62 (dd, J=11.7, 3.8 Hz, 1H),
3.57-3.48 (m, 2H), 2.32 (s, 3H).
197-198 7.26 (d, J=8.6 Hz, 2H), 7.00 (d, J=8.6
Hz, 2H), 5.69 (d, J=15.4 Hz, 1H), 5.18 (d,
J=15.4 Hz, 1H), 4.40-4.35 (dd, J=13.7,
4.9 Hz, 1H), 4.25-4.19 (m, 1H), 3.96-3.92
(dd, J=13.7, 7.9 Hz, 1H), 3.82 (s, 3H),
3.81-3.77 (m, 1H), 3.66-3.62 (dd, J=11.8,
4.0 Hz, 1H), 3.58-3.48 (m, 2H).
186-187 7.39 (d, J=8.4 Hz, 2H), 7.23 (d, J=8.4
Hz, 2H), 5.71 (d, J=15.9 Hz, 1H), 5.21 (d,
J=15.9 Hz, 1H), 4.43-4.39 (dd, J=13.8,
4.8 Hz, 1H), 4.29-4.23 (m, 1H), 3.97-3.92
(dd, J=13.4, 8.1 Hz, 1H), 3.86-3.80 (m,
1H), 3.69-3.65 (dd, J=11.8, 3.9 Hz, 1H),
3.60-3.51 (m, 2H).
65-70 7.42-7.20 (m, 5H), 4.42-4.18 (m, 3H),
4.04-3.79 (m, 3H), 3.79-3.46 (m, 3H), 2.67
(t, 2H), 2.15-2.00 (m, 2H).
182-184 7.38-7.22 (m, 5H), 4.39-4.34 (dd, J=13.6,
5.2 Hz, 1H), 4.29-4.22 (m, 2H), 3.98-3.56
(m, 6H), 3.53-3.51 (m, 1H), 2.66 (t, J=7.4
Hz, 2H), 1.77-1.59 (m, 4H).
146-148 4.43-4.38 (dd, J=13.6, 5.0 Hz, 1H),
4.30-4.20 (m, 2H), 4.01-3.97 (dd, J=13.5,
7.8 Hz, 1H), 3.89-3.80 (m, 2H), 3.65-3.54
(m, 3H), 1.74-1.70 (m, 2H), 1.30 (br, s,
6H), 0.86 (t, J=7.0 Hz, 3H).
155-157 4.48-4.43 (dd, J=13.6, 5.2 Hz, 1H),
4.27-4.24 (m, 2H), 4.05-3.96 (m, 1H),
3.90-3.82 (m, 2H), 3.74-3.54 (m, 3H,
1.74-1.70(m, 2H), 1.30 (br, m, 8H), 0.86 (t,
J=6.5 Hz, 3H)
154-156 4.44-4.40 (dd, 1H), 4.27-4.21 (m, 2H),
4.01-3.97 (dd, 1H), 3.86-3.80 (m, 2H),
3.75-3.56 (m, 3H), 1.75-1.70 (m, 2H), 1.30
(m, br, 8H), 0.86 (t, 3H).
153-155 4.53-4.48 (dd, 1H), 4.31-4.21 (m, 2H),
3.99-3.93 (m, 2H), 3.79-3.73 (m, 2H),
3.67-3.56 (m, 2H), 1.80-1.68 (m, br, 2H),
1.29 (m, 14H), 0.88 (t, J=6.5 Hz, 3H).
165-167 5.48 (t, 1H), 4.34-4.12 (m, 3H), 3.87-3.55
(m, 4H), 1.84-1.81 (m, 4H), 1.64 (d, 1H),
1.52-1.28 (septet, 4H), 1.17 (t, 1H).
189-191 4.43-4.39 (dd, 1H), 4.36-4.22 (m, 2H),
4.02-3.81 (m, 3H), 3.77-3.51 (m, 7H), 2.56
(br, s, 4H), 2.42 (t, 2H), 2.04-1.90 (m, 2H).
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lkble 5. Substituted glucamine dithiocarbamates llf-h, j-m.
Compound number R Formula, anal. Yield, % Melting point, OC 'H NMR (D20/DSS), 6, ppma
l1f C6H5(CH2)3 C16H24NNaO5S2 * 1.25 H20 75.6 179-181.5 7.39-7.24 (m, 5H), 4.42-4.26
(C,H,N,S) (m, 3H), 3.93-3.60 (m, 7H), 2.66
(t, 2H), 2.11-2.01 (m, 2H).
11g C6H5(CH2)4 C,7H26NNaO5S2 * 1.0 H20 86.1 177-179.5 7.39-7.22 (m, 5H), 4.42-4.27
(C,H,N,S) (m, 3H), 3.92-3.60 (m, 7H), 2.67
(t, 2H), 1.79-1.57 (m, 4H).)
Ilh CH3(CH2)5 C,3H26NNaO5S2 * 0.9 H20 65.0 153-155 4.76 (dd, 1H), 4.35-4.20 (m, 2H),
(C,H,N,S) 3.93-3.62 (m, 7H), 1.72 (br, s, 2H),
1.30 (br, s, 6H), 0.86 (br, t, 3H).
llj CH3(CH2)7 C15H3,,NNaO5S2 * 0.0 H20 85.7 146-150 *4.67-4.62 (dd, 1H), 4.43-4.32
(C,bH,N,S) (m, 1H), 4.26-4.17 (m, 1H),
3.87-3.70 (m, 6H), 3.65-3.60 (dd,
1H), 1.86-1.67 (m, 2H), 1.39-1.22
(m, br, 10H), 0.90 (t, 3H).
llk CH3(CH2)9 C,7H34NNaO5S2 * 0.5 H20 72.6 157-160 *4.66-4.63 (dd, 1H), 4.43-4.33
(C,H,N,S) (m, 1H), 4.25-4.18 (m, 1H),
3.87-3.59 (m, 7H), 1.86-1.70
(m, 2H), 1.34 (br, s, 14H), 0.91
(t, 3H).
11l c-C6H,, C13H24NNaO5S2 * 1.0 H20 76.3 169-170 5.48 (t, 1H), 4.24-4.10 (m, 3H),
(C,H,N,S) 3.82-3.76 (m, 4H), 3.66-3.60 (m,
1H), 1.83-1.75 (m, 4H), 1.63 (d,
1H), 152-1.27 (septet, 4H),
1.19-1.11 (m, 1H).
llm O(CH2CH2)2N(CH2)3 C14H27N2NaO6S2 * 0.0 H20 88.1 154-156 4.48-4.43 (dd, 1H), 4.37-4.29
(C,H,N,S) (m, 2H), 2.95-3.86 (m, 2H),
3.83-3.73 (m, 8H), 3.67-3.61
(m, 1H), 2.56 (t, 4H), 2.42 (t, 2H),
2.02-1.92 (m, 2H).
aIn d4-MeOH. Analysis not within + 0.40%.
bC, calculated 46.02 (found 46.56).
injections CdCl2*2.5 H20/kgin 0.5 mLof0.9% saline on
4 consecutive days. After a 3-day interval the animals
were randomly divided into groups of five each. One
groupthathadnotbeengivencadmiumserved as a nor-
mal control and was given 0.9% saline for all injec-
tions. One group in each experimental set served as
thecadmium control groupand wasgiven0.9% saline in-
jectionsinsteadofchelatingagent. Eachothergroup was
given an IP irnection of one of the chelating agents at
alevelof 1.0mmole/kgeachdayfor5consecutive days.
Each injection contained the appropriate amount of
chelatingagentin0.5mLof0.9% saline. Twodaysafter
thelastinjectionofchelatingagent, alltheanimals were
sacrificed by cervical dislocation and dissected. Weigh-
edamountsofeachanimal'sliver, kidney, andbrain were
digested in pure nitric acid on a heating block (800C),
taken to dryness, redissolved in 1% nitric acid, and
analyzed for cadmium using a Perkin Elmer model 403
atomic absorption spectrophotometer. Each separate
shipment of mice had its own control groups. The SD
found for average organ analyses covered the range of
5 to 20% and were generally larger for lower cadmium
levels. Tbbringalloftheseto a commonbasis, therelative
renal and hepatic cadmium levels for each compound
wereobtainedbydividingtheobservedcadmium organ
levelsvaluesbythecorrespondinglevelsinthecadmium
control groups. The use of none of the compounds
reportedhereresultedinanyelevationofcadmiumlevels
inthebrainsoftheanimals(datanotshown). Theselevels
were of the order of 40 to 70 parts per billion.
Ikble 6. Relative cadmium mobilizations
(Cd treated/ Cd control).a
Compound number Liver Kidney - T
2 0.97 0.86
4a 1.12 0.67
4b 0.94 0.66 -
8a 1.03 0.90 1.09
8b 1.19 0.76 1.97
8c 0.89 0.85 1.65
8d 0.66 0.52 1.07
8e 0.80 0.79 1.80
8f 0.81 0.92 1.83
8g 0.99 0.99 2.25
8h 0.73 0.83 3.21
8i 0.83 1.20 3.75
8j 1.00 1.03 4.29
8k _b _b 2.51
81 1.04 0.51 2.76
8m 0.74 0.56 0.62
l1f 0.61 0.75 1.83
11g 0.48 1.04 2.25
llh 0.94 0.83 3.21
l1j 1.17 0.96 4.29
llk 1.12 1.06 5.37
11l 0.80 0.35 2.51
llm 0.77 0.53 0.62
aAll the compounds were injected at adosage of 1.0 mmole/kg, IP
eachdayon5consecutivedaysexceptfor1Uj(0.4mmole/kg)and 11k
(0.1 mmole/kg)becauseoftheirtoxicity. Thedataonthesecompounds
were not used in the correlations.
bAll animals in thisgroupdied afteroneinjection at 1.0 mmole/kg.
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Allanimals were keptinanAALAC-approved animal
care facility during the course of the experiments and
were provided with free access to food and water. The
statisticalanalysisofthedatawascarried outusingstan-
dard analysis of variance and least squares curve-
fitting methods.
Results and Discussion
The properties of the newly prepared amines (xyla-
mine and glucamines) are given in Thbles 1 and 2. The
novel dithiocarbamates derived from them and their
characteristics are given in TIble 3 (amino acid deriva-
tives), lhble4(xylamine dithiocarbamates), and Ihble 5
(glucamine dithiocarbamates). Thereactionsusedinthe
preparation of these compounds are shown in Figures
1, 2, and 3, respectively.
The search for parameters that correlate with the in
vivofindingsis, mostobviously, centered onthoserelated
to the presumption that the ability of the dithiocar-
bamate to passthroughthecellularmembrane iscrucial
tothe successoftheoveralldecorporation process. This
suggeststhe nparameterofHansch andLeo(32), though
anumberofrelatedparametershaveserved inthe same
fashion (33,34). The correlation of relative cadmium
levelsintheliverandkidneyfollowingastandardchelate
treatment has been examined. In all cases the summa-
tionsoftheparameters(1n)usedtocharacterizethe com-
poundshaveinvolved allofthosepartsofthemolecular
otherthanthedithiocarbamate grouping [-N(CS2Na)-J.
We have used standard procedures (32) to obtain an
estimate of the contribution of the morpholine group
(8m, llm) to our parameters.
'lble 6containsdata ontherelative efficaciesofthese
compounds in removing cadmium from the liver and
kidneyofmicepreviously loaded with 10 mgCdCI2 * 2.5
H20/kg, IP. For purposes of comparison, sodium N-
benzyl-D-glucamine dithiocarbamate monohydrate,
under comparable conditions, reduced liver levels to
0.78, which are those of the cadmium control animals,
andrenallevelsto0.51, which arethose ofthecadmium
controls (34).
The correlation of the cadmium mobilizing efficacy
withthestructuresofthevariousdithiocarbamates was
examinedusingthenparametersofHanschandLeo(32),
supplemented by values from Martin(35) and Thte (31)
where necessary. Thble 6 shows the relative reductions
observed in cadmium burdens for both the liver and
kidney. Eachseriesofcloselyrelatedcompounds was ex-
amined separately. For the glucamine dithiocarba-
mates, the correlation observed for the reductions in
renal cadmium levels with the compounds listed
(llf-llm), whencombinedwithdata onfourcompounds
published previously (34) it was found to be described
by the equation:
Scheme I
[-HNOCOOC2HS 2NaOH,CS2 N3--=S C O N a
SNa
1
H R,COOH
R..
2NaOH, CS2 t
Doxane
3 a,b
2
SNa
C=S
N COONa
R
4 a,b
a, R = H
b, R = OH
FIGURE 1. Reaction scheme showing the preparation of the com-
pounds, 2, 3a,b, and 4a,b.
Scheme H
Ar 1 H2IPIO
R-NH2 + CHO -6 70°C R-N=-CH MEOH
(CHOH)3 (CHOH)3 45-50°C
CH20H _ CH2OH-
SchiffBase
5 a-m 6
a, R = C6HSCH2
b, R = 3-CF3C6H4CH2
c, R = 4-CH3C6H4CH2
d, R = 4-CH3OC6H4CH2
e, R = 4-ClC6H4CH2
f, R = C6H5(CH2)3
g, R =C6H5(CH2)4
h, R = CH3(CH2)5
i, R = CH3(CH2)6
j, R = CH3(CH2)7
k, R = CH3(CH2)9
1, R = -C6H
m, R = C (CH2)3
RH (NCHOH)3 H
CH20H
7 a-m
INaOH, CS2
Dioxane
R'N-'--(CHOH)3
SNa CH20H
SNa
8 a-m
FIGURE 2. Reaction scheme showing the preparation of the
xylamines, 7a-m, andthecorrespondingdithiocarbamates, 8a-m.
Scheme III
R-NH2 + CHO Ar 4
60-70°C
(CHOH)s
CH2OH
5 f-hj-m 9
f, R = C6HS(CH2)3
g, R = C6HS(CH2)4
h, R = CH3(CH2)5
j, R = CH3(CH2)7
k, R = CH3(CH2)9
1, R = c-C6Hll
m, R =Cf (CH2)3
FR-N=CH
ICHOH)4
CH2OHJ
SchiffBase
H2/PtO2 _
MeOH N'- (CIHOH)4 45-50 °C H
CH20H
10 f-h,j-m
NaOH, CS2
Dioxane
RN CH2OH)
f=S CH20H
SNa
11 f-hj-m
[Cdtreated/Cdcontro}l
= 1.918 + 1.055(yir) + 0.174(yTr)2
n = 10; r = 0.937; s = 0.51; 0.0001 < p S 0.005
FIGURE 3. Reaction schemeshowingthe preparation ofglucamines
lOf-hand lOj-m, andthecorrespondingdithiocarbamates, llf-h,
and llj-m.
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This relationship has a minimum at li = -3.02, which
indicates that the optimally effective compounds (i.e.,
thosewhichgivethelowestresidualcadmiumlevels)are
expected tohavevaluesoflit whichare closeto -3.00.
Forthehepaticdataobtainedwiththeglucaminederiva-
tive, no reliable correlation with lIn was found, though
therelative reductions correlated toanextentwiththe
molecular weight (MW) ofthe dithiocarbamate via the
equation:
[Cdtreated/Cdcontrol = -0.005(MW) + 2.758
n = 10; r = 0.74; s = 0.45; 0.01 < p < 0.025
This relationship is consistent with the fact that these
compounds cause predominantly biliary excretion,
which is favored by higher molecular weights.
Thexylaminedithiocarbamates arealmostuniformly
less effective than the corresponding glucamines. The
correlation of lit with renal cadmium level reductions
for the xylamines is given by the equation:
(Cdtreated/Cdcontrol] = 1.07 + 0.295(lTr) + 0.04(ln)2
n = 12; r = 0.735; s = 0.50; 0.025 < p < 0.05
Thelowervalueofrindicatesthatthiscorrelationisnot
sosatisfactoryasthatobtainedforrenalcadmiumlevels
withtheglucaminedithiocarbamates. Onlythreeofthe
xylamine derivatives were quite effective in reducing
renalcadmiumlevels(8d, 81, and8m).rible6showsthat
some compounds that are very effective in reducing
hepatic cadmium levels are not effective in reducing
renalcadmiumlevels(e.g., llg). Ingeneral, thexylamine
dithiocarbamates are less effective thanthe glucamine
dithiocarbamates, sometimes by very appreciable
amounts. Of the newly prepared compounds reported
herethatarequiteeffective(8d, 8m, 111, and llm), three
(8d,8m, and llm)arecapableofforminghydrogenbonds
via oxygen atoms in the substituent group. The fourth
compound, 111, thecyclohexylderivative, ismoreeffec-
tivethanitsxylamineanalog, especiallyinremovingcad-
mium from the liver. Compounds 2, 4a, and 4b, all of
which have ionized carboxylic acid groups at physio-
logical pH, have relatively little effect on hepatic cad-
miumlevels, thoughtheyaremoreeffectiveinreducing
kidney cadmium levels. Several of the compounds in
Thble 6(i.e., 8d, 8m, 111, and llm) are approximately as
effective as the parent benzyl-D-glucamine dithiocar-
bamate. Compound 111 is expected to be very similar
structurally totheparentbenzyl compound. Dithiocar-
bamate treatment may cause cadmium in other organs
to migrate towards the liver(36,37), so atemporary in-
crease in liver cadmium may be found for some dithio-
carbamates and dosing schedules.
Itisofsomeinteresttoexaminethosecompoundsthat
are both better and worse than anticipated. One such
compound is the 4-phenylbutyl derivative (llg) of D-
glucamine, which is very ineffective in removing renal
cadmium andveryeffectiveinremovinghepaticcadmi-
um. The cyclohexyl derivatives of both xylamine- (81)
and D-glucamine dithiocarbamates (111) are very effec-
tive in removing renal cadmium, but the D-glucamine
derivative is superior here, as elsewhere, in removing
cadmiumfromtheliver. Thedithiocarbamatesthatcarry
alkylchainswerequitedisappointing, astheywereboth
relatively more toxic and much less effective than an-
ticipated. The fact that none ofthe alkyl derivatives is
amongthe most effective compounds indicatesthat, in
additiontoanyrequirementsbasedoni (polarity), there
are structural or geometric requirements for optimum
efficacy that cannot be satisfied easily by an unsubsti-
tutedalkylgroup. Thereisaconsiderableincreaseinthe
toxicity and decrease in the efficacy with an increase
inthechainlengthofthepurelyalkylxylamine(8h-8k)
and D-glucamine (llh-llk) dithiocarbamates.
Because the kidney is amuch smaller organ than the
liver, acompoundthatisveryeffectiveinmobilizingonly
hepaticcadmiummayproduceamuchmorepronounced
decrease in the whole body cadmium-burden than one
that is equally effective in mobilizing only renal cad-
mium. The removal of renal cadmium may prove more
important, asrenaldamageisthefirstandalsothemost
serious consequence of chronic cadmium intoxication
(38).
Thestructuralfeaturesrequiredforsubstantiallymo-
bilizing hepatic cadmium are not generally coincident
withthoseforrenalcadmium. Thismayberelatedtothe
requirements forbiliary excretion ofthe resulting cad-
miumcomplexes, wherethepresence ofnonionicpolar
groupsisquiteimportant(11). Withveryfewexceptions,
of which llg is the most notable, the enhancement of
renalcadmiummobilizationisaprerequirementforthe
enhancement of hepatic cadmium mobilization.
Acomparison ofthe compounds described here with
those reported earlier on the mobilization of cadmium
by dithiocarbamates is very useful in allowing certain
generalcharacteristics ofeffectiveandineffective com-
pounds to be seen more clearly. In an examination of a
series of compounds closely related to sodium diethyl-
dithiocarbamate (6,8), RlR2NCS2Na, it was shown that
ifR1 = R2 = C2H5 orCH3, cadmium mobilizationwasac-
companiedbythe transportofcadmium intothebrain;
if either R1 or R2 = CH2COOH, the compounds were
ratherineffective at mobilizingintracellular cadmium.
Finally, ifeither R1 or R2 (orboth) = CH2CH2OH, while
the otherwasamethyl, ethyl, orP-hydroxyethylgroup,
cadmiummobilizationoccurredwithasignificantreduc-
tioninthe cadmium transporttothebrain. Ofthe com-
poundsexaminedatthattime,(HOCH2CH2)2NCS2Nawas
theleasttoxicandcarriedtheleastcadmiumtothebrain
(5,6). This compound, unfortunately, did not possess
satisfactory stability at room temperature. The search
for a compound of superior stability lead to HOCH2-
(CHOH)4N(CH3)CS2Na whichproved to be a compound
of low toxicity, excellent stability, and as effective as a
cadmiummobilizingagent whengivenat2.2mmole/kg
(9). Two piperidine derivatives:; HOCH-(CH2CH2)2
NCS2Na and H2NCOCH(CH2CH2)2NCS2Na were also
foundtobeveryeffectivewhengivenatthislevel(7,39).
367SINGH, JONES, ANDJONES
A series of compounds prepared from the primary
amines,RI = HandR2 = CH3, C2H5, n-C3H7, n-C4H9 pro-
vedtohavetheabilitytomobilizecadmium, buthadpoor
chemical stability and were too toxic (40).
AverysignificantstepwasKojimaandhisco-workers
findingthatreplacement ofthemethylgroupinHOCH2-
(CHOH)4CH2N(CH3)CS2Na by a benzyl group to give
HOCH2(CHOH)4CH2N(CH2C6H5)CS2Na resultedinacom-
poundthatwasbothsignificantly moreeffectiveandeq-
ually nontoxic (41). The corresponding 4-methylbenzyl
and4-isopropylbenzyl compounds werealsoquiteeffec-
tive(33). TheapplicationoftheToplissproceduretothis
series ofcompounds, with aplanned range ofsubstitu-
tions on the benzene ring, showed that of the 4-Cl,
4-CH30, 4-CH3, 3-CF3 derivatives and the parent com-
pound, the 4-CH30 was significantly superior to all of
the others on the basis ofreductions it effected in both
renalandhepaticcadmiumlevels(34). Studiespreviously
published (15,33,34,41-43) showed clearly the advan-
tages of what may be called an amphipathic chelating
agent, i.e., one containing both a polar and a nonpolar
grouponthenitrogenatom. Thepreparationandexami-
nation of the cyclohexyl derivatives (c-C6H11)NRj-
(CS2Na), whereR, = CH2CH2SO3Na, CH2CH2CH2SO3Na
and CH2CH(OH)CH2SO3Na showed that more than one
category of amphipathic carbodithioates is capable of
mobilizing cadmium in an impressive fashion (15); the
higherdosage requiredfortheselatterthreecompounds
shows that the presence ofacharged group(SO3) intro-
ducestoogreatapolarity tobeadequatelybalanced by
a cyclohexyl group for optimum efficacy. The related
compounds 81 and 111, which bear uncharged polar
groupsareeffectiveatsignificantlylowerdosagelevels.
Ofthecompoundsnewlyreportedhere, three(8m, 111,
and llm)areequalorsuperiorindecreasinghepaticand
renal cadmium to sodiumN-benzyl-D-glucamine dithio-
carbamate, reportedbyKojimaandhisco-workers(41),
which is the most effective of such compounds previ-
ously reported from other laboratories.
Conclusion
Cadmiumcanbemobilizedfromitsagedintracellular
depositsinrodentsbyavarietyofdithiocarbamates. The
mosteffective ofthese areamphipathicchelatingagents
inwhichthenitrogenbearsbothapolarand anonpolar
substituent. The efficacy of a particular compound is
dependent upon the balance achieved between these
two groups. If the compound bears an ionizable polar
group, efficacy decreases, presumably because of the
greaterdifficultyinpassingthroughcellularmembranes.
If the compounds are too nonpolar, they have an en-
hanced toxicity and generally cause an increase in the
cadmium content ofthebrain. The mosteffective com-
pounds include those structures thatbearaD-glucamine
residueandasubstitutedbenzylora3-(4-morpho-linyl)/
propylresiduethatiscapableofforminghydrogenbonds.
Analogous structures bearing a cyclohexyl group are
quiteeffectiveinremovingrenalcadmium, buttheyare
less effective in removing cadmium from hepatic sites.
The trend shown in the correlation equations given,
wheregreaterefficaciesarefoundforglucaminedithio-
carbamates at an optimum Iin value around -3.00, as
well as the known lowerefficacies ofcompoundsbear-
ing charged groups such as SO3 or COO-, which have
large negative In values, indicates the existence of a
regionofmaximumefficacyasXi changes. Suchatrend
has been found in many other studies involving these
parameters (31,35).
Thedosagelevelsatwhichthe mosteffectiveofthese
compoundshavedemonstratedtheirefficacyinanimal
testsarestilltoohigh(byafactorofabout5)tobegiven
seriousconsiderationforclinicaluse. Onthebasisofthe
compounds examined so far, it is reasonable to suspect
thatsuchacompound canbepreparedbytheappropri-
ateexploitationofthe structural informationcurrently
on hand.
Thegeneraltrendsfoundheremayproveusefulinthe
designofchelatingagentsforthedecorporationofother
toxicmetalsthataretightlybound to intracellularsites
in vivo. It should be noted that the fraction of intra-
cellular cadmium mobilized with the most effective of
these chelatingagents is quite high. An analogous pro-
blemofthemobilization ofintracellulardepositsoftox-
ic metal is also important in cases ofplutonium intoxi-
cation(44,45), ironoverloadfromrepeatedtransfusions
(16-18), and lead intoxication (46).
Ourresultssuggestthatthepresenceoflargenumbers
ofionized substitutents onachelate structure can con-
stitute a major deterrent to accessing that chelating
agent to intracellular deposits of toxic metals. At the
presenttimethechelatingagentsusedforplutoniumand
lead and most ofthose used for iron possess such ionic
groups. Thusitisnotuncommontotestchelatingagents
for plutonium mobilization by irjecting them into the
animals a few minutes after the administration of the
plutonium (44). It would appear that related chelate
structures, without such a preponderance of ionized
groups, mightprovesignificantlysuperiortothosecom-
pounds currently used or underinvestigation forthese
twoelements. Itmustalsoberealized, however, thatthe
presenceofasuitablenumberofpolar(butnotnecessari-
ly ionic) groups will usually also result in a significant
decrease in the toxicity of the basic struc-
ture. Ourresultsalsosuggestthatvariationsofthechel-
atingagentstructureneedtoconsidertheoptimization
ofthe balance ofpolar and nonpolar groups to achieve
membranepermeability, afactorthatmayprove useful
inimprovingtheremovalofintracellulardepositsoftoxic
metals other than cadmium.
Thisinvestigation hasbeensupported by the National Institute of
Environmental Health Sciences under grant ES-02638.
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